EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer

Sandra A Frimpong, Benjamin A Teply iD

Translational Cancer Research · 2025-06 · 14 (6) · 3281-3285

DOI: 10.21037/tcr-2025-232 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Cancer Research, 2025-06. Verfasst von Sandra A Frimpong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

to last follow-up for alive patients were calculated from the time of study enrollment

Schlagwörter

Stichwörter der Autor:innen

Prostate cancerandrogen receptor signaling inhibitors (ARSIs)biomarkersprognostic genes

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
  • Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

ORCID-Profile: Benjamin A Teply

Zitieren

APA

Frimpong, S. A., & Teply, B. A. (2025). Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer. Translational Cancer Research, 14(6), 3281-3285. https://doi.org/10.21037/tcr-2025-232

Vancouver

Frimpong SA, Teply BA. Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer. Translational Cancer Research. 2025;14(6):3281-3285. doi:10.21037/tcr-2025-232

BibTeX
@article{Frimpong2025,
  author = {Frimpong, Sandra A and Teply, Benjamin A},
  title = {Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer},
  journal = {Translational Cancer Research},
  year = {2025},
  volume = {14},
  number = {6},
  pages = {3281--3285},
  doi = {10.21037/tcr-2025-232}
}
Kostenlos starten →